PM
XERS icon

Prosight Management’s Xeris Biopharma Holdings XERS Stock Holding History

Prosight Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-419,469
Closed -$1.12M – 60
2020
Q2 		$1.12M Buy
+419,469
New +$1.46M 0.48% 45

Other funds holding XERS

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's XERS Position: Q3 2020 in Review

Prosight Management sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 419,469 shares — an estimated $1.12M sold.

Prosight Management first reported a position in XERS in Q2 2020 and held it in 1 quarter. The position peaked at $1.12M in Q2 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • Prosight Management reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • Prosight Management sold 419,469 Xeris Biopharma Holdings shares in Q3 2020, an estimated $1.12M.
  • Prosight Management first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 1 quarter.
  • Prosight Management's Xeris Biopharma Holdings position peaked at $1.12M in Q2 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.